Ergocalciferol
FDA-approved product (capsule, oral), marketed as Deltalin, Drisdol, Ergocalciferol and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Hypoparathyroidism
- Hypophosphatemia
- Hypophosphatemic rickets
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Vitamin d and analogues
- FDA pharmacologic class
- Provitamin D2 Compound FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA46.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ergocalciferol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00288873 · start 2006-02
Registered record
- Registry ID
- NCT00288873
- Conditions
- Vitamin D Deficiency; Secondary Hyperparathyroidism; Obesity
- Interventions
- Ergocalciferol; Cholecalciferol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-02
- Completion
- 2007-07
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVitamin D Deficiency; Secondary Hyperparathyroidism; ObesityInterventionErgocalciferol; CholecalciferolPhasePhase 4Registry statusCompletedTreatment of Hypovitaminosis D in Rheumatoid Arthritis
NCT00423358 · start 2005-02
Registered record
- Registry ID
- NCT00423358
- Conditions
- Rheumatoid Arthritis; Hypovitaminosis D
- Interventions
- Vitamin D; placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-02
- Completion
- 2009-02
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRheumatoid Arthritis; Hypovitaminosis DInterventionVitamin D; placeboPhaseNot applicableRegistry statusCompletedEffects of Vitamin D Supplementation on Antimycobacterial Immunity
NCT00157066 · start 2002-12
Registered record
- Registry ID
- NCT00157066
- Conditions
- Tuberculosis
- Interventions
- Ergocalciferol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-12
- Completion
- 2006-09
- Enrolment
- 230
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionErgocalciferolPhaseNot applicableRegistry statusCompletedVitamin D Administration in the Nursing Home
NCT00204919 · start 2001-06
Registered record
- Registry ID
- NCT00204919
- Conditions
- Vitamin D Deficiency; Osteoporosis
- Interventions
- Vitamin D; placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2004-11
- Enrolment
- 96
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVitamin D Deficiency; OsteoporosisInterventionVitamin D; placeboPhaseNot applicableRegistry statusCompletedStudies With 1,25-Dihydroxycholecalciferol
NCT00001151 · start 1976-03
Registered record
- Registry ID
- NCT00001151
- Conditions
- Hypocalcemia; Rickets
- Interventions
- 1,25-Dihydroxycholecalciferol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 1976-03
- Completion
- 2009-10
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypocalcemia; RicketsIntervention1,25-DihydroxycholecalciferolPhasePhase 2Registry statusTerminated